IPO Window Opens on Two Tracks as SEC Rewrites Market Plumbing

The late-July IPO cohort delivered what looks, at first glance, like a contradictory verdict on the new-issue market. A sleep-apnea biotech priced above its range and jumped 56% on day one. A national sandwich chain priced at the midpoint of its range and finished its first session below the offer. Read together, though, they tell a coherent story: the window is open, but it discriminates sharply by catalyst. And while issuers and investors sort through that signal, the SEC is moving to rewrite the plumbing underneath all of it — proposing to rescind the Order Protection Rule after two decades and greenlighting a Nasdaq overnight session that could start trading 23 hours a day before year-end.

Two IPOs, Two Verdicts

Apnimed (APMD) raised $192 million in an upsized IPO on July 30, 2026, selling 12 million shares at $16 — above the initially marketed range of $14 to $16 for 10 million shares. The stock opened at $22, was halted for volatility, and closed at $25, a 56% first-day gain that valued the company near $1 billion.^[1] The lead candidate, an oral therapy for obstructive sleep apnea, is under FDA review — a concrete, near-term regulatory catalyst that investors could underwrite.

Jersey Mike’s Subs (JMKE) took a different path. Backed by Blackstone and the Abu Dhabi Investment Authority, the sandwich chain offered 43.5 million Class A shares at $23 — the midpoint of a $21–$25 range — raising roughly $1 billion. Shares opened at $21, 8.7% below the offer price, and closed at $21.63, down about 6% from the IPO price.^[2] The company’s filing showed that selling stockholders — not the company — offered 29.7 million of the 43.5 million shares, meaning roughly two-thirds of the deal was secondary in nature despite the IPO label.^[2]

The divergence is not random. Apnimed offered a binary catalyst with asymmetric upside potential — an FDA decision that could open a multi-billion-dollar oral sleep-apnea market. Jersey Mike’s offered steady-state restaurant growth with a controlling-selling-holder overhang and only 18 months of private-equity ownership before the flip. The market is not closed. It is pricing catalyst probability and holder posture with unusual precision.

The Biotech Pipeline Behind Apnimed

The biotech window that Apnimed kicked open has at least three more names queued. Attovia Therapeutics (ATTO), Braveheart Bio (BRVE), and Vogenx have each set IPO terms targeting a combined raise of more than $500 million.^[3]

Attovia, a clinical-stage biopharmaceutical company headquartered in San Carlos, California, is developing next-generation biologics for immune-mediated diseases using its ATTOBODY nanobody platform.^[4] At the $16 midpoint, the deal would net approximately $182 million, supplementing the $132.6 million in cash Attovia held at the end of March.^[3] Apnimed’s 56% pop — with the stock halted for volatility intra-day — is the kind of aftermarket performance that typically pulls more issuers off the fence, and the Attovia/Braveheart/Vogenx cluster suggests that dynamic is already in motion.

The base-rate read here matters. Biotech IPOs have historically clustered in waves: a strong debut draws filings within weeks, and a weak one shuts the window for months. The Apnimed reception was strong enough — oversubscribed, upsized, halted up — that the probability of the pipeline clearing in the third quarter looks meaningfully higher than it did two weeks ago. Whether that extends beyond biotech into the consumer and technology names that have been waiting in the wings is a separate question, and Jersey Mike’s provides a cautionary data point.

The SEC Proposes Rescinding the Order Protection Rule

While the IPO market sorts issuers by catalyst, the SEC is proposing the most significant structural rewrite of U.S. equity trading in two decades. On June 11, 2026, the Commission proposed amendments to rescind Rule 611 of Regulation NMS — the Order Protection Rule, also known as the trade-through rule — and Rule 610(e), the prohibition on locked and crossed quotations.^[5]

Rule 611, adopted in 2005, requires trading centers to execute orders at the best displayed price across all markets, preventing “trade-throughs” where an inferior price is taken while a better quote exists elsewhere. Rule 610(e) bars markets from displaying quotes that lock or cross one another. Together, these rules form the backbone of the fragmented, multi-venue equity market structure that has operated for the last 20 years.

SEC Chairman Paul Atkins framed the proposal as long-overdue cleanup: “After two decades of Rule 611, it is high time that the Commission review its unintended consequences that have hindered — rather than enhanced — the long-term growth of our markets.”^[5] The proposal would also rescind related defined terms in Rule 600 and make conforming changes to other provisions. The public comment period remains open for 60 days following Federal Register publication.^[6]

What rescission would mean in practice is a genuine open question — which is precisely why the balanced view matters. On one reading, removing the trade-through rule could simplify execution, reduce the routing complexity and rebate arbitrage that currently fragments order flow across 16+ trading venues, and let competition and innovation shape market evolution. On another, it could allow larger exchanges with deeper liquidity to internalize order flow without obligation to route to better-priced competing venues, concentrating execution and degrading price improvement for smaller orders. The locked-and-crossed prohibition, if lifted, would allow markets to display simultaneous bid and ask prices that overlap — something currently suppressed by rule, which some argue creates artificial friction and others argue prevents dysfunction.

The Sidley analysis called the proposal “one of the most significant” market-structure changes in recent memory,^[6] and Commissioner Mark Uyeda’s statement described it as “an important beginning in the broader, more complex journey of reforming the Commission’s equity market-structure rules.”^[6] The 60-day comment window will reveal how market makers, exchanges, and institutional investors position themselves on what comes next.

Nasdaq’s 23/5 Trading Session and Overnight Price Bands

The Reg NMS proposal does not exist in isolation. In April 2026, the SEC approved Nasdaq’s plan to extend trading hours to 23 hours a day, five days a week, with a new overnight session running from 9:00 p.m. to 4:00 a.m. ET, Sunday through Thursday.^[7] The exchange has signaled a target launch date of December 6, 2026.^[7] NYSE Arca filed a parallel proposal for its own overnight trading session in May 2026.^[8]

The overnight session creates a structural gap: the existing Limit Up-Limit Down (LULD) framework, designed for the regular session, does not automatically extend to overnight hours. To bridge this, Nasdaq and other NMS plan participants filed the Twenty-Seventh Amendment to the Plan to Address Extraordinary Market Volatility on May 27, 2026, proposing temporary price band protections for overnight trading.^[9] The approach is deliberately two-phase: interim protections modeled on mechanisms already used by alternative trading systems to limit sharp price swings in individual securities, followed by a data-gathering period before a permanent framework is finalized.^[9]

Nasdaq’s own rulebook already shows the plumbing being laid. Rule 4120 was amended to halt trading at the conclusion of the Day Session at 8:00 p.m. ET and resume with the Night Session at 9:00 p.m. ET, with outstanding orders cancelled at session boundaries.^[10] The “CORE FIX” references — the exchange’s new core matching engine — are slated for 2026 implementation.^[10]

The interaction between the Reg NMS rescission proposal and the 23/5 expansion is where the trajectory gets interesting. Rescinding the Order Protection Rule changes how orders are routed during regular hours. Adding an overnight session with only interim price bands changes how risk is managed outside them. Doing both simultaneously — without a finalized volatility framework for the overnight window — means the market is rebuilding the bridge while traffic is already starting to cross it. The probability that this proceeds without at least one notable overnight volatility event before the permanent framework is in place is not high. The SEC’s own filing references the May 6, 2010 Flash Crash as the motivating precedent for the original LULD plan.^[9]

AB InBev Secondary: The €752 Million Block

On the secondary side, E.P.S. SA, a major AB InBev shareholder, placed approximately 10 million AB InBev shares worth roughly €752 million (~$867 million) via JPMorgan, with books closing on August 3, 2026.^[11] E.P.S. currently holds over 67 million AB InBev shares; the placement represents about a 15% reduction of its position. This follows the earlier Altria-led secondary offering of 35 million AB InBev shares in March 2024, which also included a concurrent buyback — a pattern of shareholder rotation that has been a steady source of large-block supply in the consumer staples sector.

The AB InBev placement is a reminder that secondary supply — not just new IPOs — shapes the liquidity equation. Large blocks from existing holders can absorb demand that might otherwise rotate into new issues, and the €752 million ticket is roughly four times the size of Apnimed’s entire IPO raise.

What to Watch Next

1. Attovia (ATTO) pricing and debut — Expected to list on Nasdaq on August 5, 2026, with 12.5 million shares at $15–$17.^[4] If it clears with an upsized deal and a positive first-day print, the biotech IPO window is firmly open. A break below range would be the first signal that Apnimed’s reception was company-specific rather than sector-wide.

2. Reg NMS comment letters — The 60-day comment window closes in mid-August. The substance and volume of submissions from major market makers, exchanges, and institutional investors will indicate whether rescission proceeds smoothly or faces pushback that delays or softens the final rule.

3. Nasdaq 23/5 launch readiness — The December 6, 2026 target is firm but contingent on overnight price band protections being operational. Watch for the permanent overnight LULD framework filing, which will signal whether the launch date holds.

4. Jersey Mike’s (JMKE) first-week stabilization — Whether the stock recovers toward the $23 offer or continues to trade below it will inform how the market prices deal structure (large secondary component, short PE holding period) versus fundamentals for upcoming consumer IPOs.

5. Additional biotech filings — If Braveheart and Vogenx price successfully in August, expect at least two to three more S-1 filings in the biotech sector within the month, following the historical pattern of post-wave clustering.

The throughline is that issuance and market structure are both in transition. The IPO market is open but selective — rewarding catalysts and penalizing holder overhangs. The regulatory framework is being disassembled and rebuilt at the same time the trading day is being extended into hours that have never had formal volatility protections. For participants, the near-term question is whether the plumbing can handle the volume before the new rules are final. The trajectory says December will be the test.